147 related articles for article (PubMed ID: 2904119)
1. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
Nomoto M; Stahl S; Jenner P; Marsden CD
Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
[TBL] [Abstract][Full Text] [Related]
2. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
Smith L; De Salvia M; Jenner P; Marsden CD
Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
[TBL] [Abstract][Full Text] [Related]
3. Antiparkinsonian activity of a single oral dose of PHNO.
Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
[TBL] [Abstract][Full Text] [Related]
4. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
[TBL] [Abstract][Full Text] [Related]
5. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
[TBL] [Abstract][Full Text] [Related]
6. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
Koller W; Herbster G; Gordon J
Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
[TBL] [Abstract][Full Text] [Related]
7. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets.
Pearce RK; Smith LA; Jackson MJ; Banerji T; Scheel-Krüger J; Jenner P
Mov Disord; 2002 Sep; 17(5):877-86. PubMed ID: 12360536
[TBL] [Abstract][Full Text] [Related]
8. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Pearce RK; Banerji T; Jenner P; Marsden CD
Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
[TBL] [Abstract][Full Text] [Related]
9. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
Goulet M; Madras BK
J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
[TBL] [Abstract][Full Text] [Related]
10. The effect of intracerebroventricular infusion of (+)-4-propyl-9-hydroxynapthoxacine (PHNO) through a totally implanted drug delivery system in rats with dopamine deficiency.
de Yebenes JG; Fahn S; Jackson-Lewis V; Mena MA
Mov Disord; 1987; 2(4):291-9. PubMed ID: 2904650
[TBL] [Abstract][Full Text] [Related]
11. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
[TBL] [Abstract][Full Text] [Related]
12. Antiparkinsonian efficacy of a novel transdermal delivery system for (+)-PHNO in MPTP-treated squirrel monkeys.
Rupniak NM; Tye SJ; Jennings CA; Loper AE; Bondi JV; Hichens M; Hand E; Iversen SD; Stahl SM
Neurology; 1989 Mar; 39(3):329-35. PubMed ID: 2784549
[TBL] [Abstract][Full Text] [Related]
13. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
[TBL] [Abstract][Full Text] [Related]
14. Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.
Temlett JA; Quinn NP; Jenner PG; Marsden CD; Pourcher E; Bonnet AM; Agid Y; Markstein R; Lataste X
Mov Disord; 1989; 4(3):261-5. PubMed ID: 2571082
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
[TBL] [Abstract][Full Text] [Related]
16. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
[TBL] [Abstract][Full Text] [Related]
17. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
18. Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
Irifune M; Nomoto M; Fukuda T
Eur J Pharmacol; 1993 Jul; 238(2-3):235-40. PubMed ID: 8104807
[TBL] [Abstract][Full Text] [Related]
19. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
Jackson MJ; Al-Barghouthy G; Pearce RK; Smith L; Hagan JJ; Jenner P
Pharmacol Biochem Behav; 2004 Nov; 79(3):391-400. PubMed ID: 15582011
[TBL] [Abstract][Full Text] [Related]
20. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
Iravani MM; Tayarani-Binazir K; Chu WB; Jackson MJ; Jenner P
J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
